{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-24-000030","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.071245+00:00","generated_at":"2026-05-31T13:45:06.620597+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Travere Q2 FILSPARI sales $27.1M, up 37% Q/Q; 521 new patient start forms","bullets":["Net product sales $52.2M (incl. $27.1M FILSPARI); total revenue $54.1M.","Net loss $70.4M ($0.91/share); adjusted net loss $50.1M ($0.65/share).","Cash & equivalents $325.4M at June 30, 2024.","PDUFA target date Sept 5, 2024 for FILSPARI full approval in IgAN.","Received 521 PSFs in Q2; 2,484 total since launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-24-000030","json":"https://secwatch.observer/filing/0001438533-24-000030.json","markdown":"https://secwatch.observer/filing/0001438533-24-000030.md","text":"https://secwatch.observer/filing/0001438533-24-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000030/0001438533-24-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000030/tvtx-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:45:06.620597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}